Pharmacology
Which Indian traditional medicines are being eyed for COVID-19?
Open access · cc by · source: Europe PMC
This review prioritizes AYUSH formulations and Indian plants with antiviral, immunomodulatory, and anti-inflammatory records for COVID-19 testing amid India’s then-<1.5% case fatality narrative.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Inspect source passages
Which Indian traditional medicines are being eyed for COVID-19?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
India case fatality rate cited below 1.50%.
case fatality rate is below 1.50%
More than 50% of discussed trials sponsored by government/AYUSH stakeholders.
More than 50% of these trials were sponsored by the government and various stakeholders associated with the Ministry of AYUSH
Key findings
Authors argue routine immunomodulator plant/AYUSH use may relate to India’s relatively lower reported fatality, highlight immunity-enhancing/anti-inflammatory/antiviral herbal evidence, note >50% of related trials linked to Ministry of AYUSH stakeholders, and urge priority preclinical/clinical testing of promising leads.
Methodology
Reviewed AYUSH-recommended formulations/ingredients, commonly used Indian medicinal plants, and plants with antiviral/immunomodulatory/anti-allergic–anti-inflammatory reports, categorizing them for research prioritization and summarizing ongoing AYUSH clinical-trial activity.
Limitations
Not an RCT proving any named herb cures COVID-19; causal claims about national fatality rates are speculative.
Related papers in this topic
Same topic cluster — not a recommendation engine.